Language selection

Search

Details for: AVASTIN

Company: HOFFMANN-LA ROCHE LIMITED

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02270994AVASTINBEVACIZUMAB25 MG / MLSOLUTIONINTRAVENOUS
Search Reported Side Effects Report a Side Effect

Summary Reports

Summary Basis of Decision
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - Avastin (bevacizumab) - Assessing the Potential Risk of Damage in Bones other than the Jawbone in Adult Cancer Patients
Summary Safety Review - AVASTIN (bevacizumab) - Assessing the Potential Risk of Irreversible Vocal Cord Damage (vocal cord necrosis)
Summary Safety Review - AVASTIN (bevacizumab) and LUCENTIS (ranibizumab) - Thrombotic Microangiopathy

Consumer Information

The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.

Date modified: